Company Filing History:
1 out of 5 
1 out of 47 
1 out of 1 Years Active: 2005
Title: Jacob Dankert - Innovator in Antimicrobial Peptides
Introduction
Jacob Dankert, an inventive mind from Baambrugge, Netherlands, has made significant contributions to the field of antimicrobial research. With one patent to his name, he has focused on developing innovative solutions to combat infections caused by bacteria and fungi.
Latest Patents
Dankert's patent involves "Isolated and recombinant antimicrobial peptides thrombocidin-1 (TC-1) and thrombocidin-2 (TC-2), or variants thereof." This groundbreaking invention presents antimicrobial peptides that exhibit activity against both gram-positive and gram-negative bacteria. These peptides are also effective against fungi, making them valuable in treating various infections. The invention highlights the use of these peptides in creating medicaments for treating bacterial or fungal infections, such as endocarditis, in humans and animals. Furthermore, the peptides can be utilized in release systems to prevent such infections, showcasing the broad potential of his work.
Career Highlights
Jacob Dankert has worked with esteemed institutions, including the Academic Medical Center at the University of Amsterdam and the University of Twente. His work in these prominent research environments has helped foster innovation in medical science and antimicrobial treatments.
Collaborations
Throughout his career, Dankert has collaborated with other notable professionals in the field, including Jeroen Krijgsveld and Sebastianus Antonius Johannes Zaat. These partnerships have likely contributed to the advancement of his research and the successful development of his patented solutions.
Conclusion
Jacob Dankert's contributions to antimicrobial peptide research position him as a noteworthy inventor in the realm of medical innovations. His dedication to developing effective treatments for bacterial and fungal infections demonstrates the importance of inventive minds in addressing healthcare challenges. As his career progresses, further advancements from Dankert are anticipated in the field of antimicrobial research.